MX2013006874A - Compuestos ariciclico continuo. - Google Patents

Compuestos ariciclico continuo.

Info

Publication number
MX2013006874A
MX2013006874A MX2013006874A MX2013006874A MX2013006874A MX 2013006874 A MX2013006874 A MX 2013006874A MX 2013006874 A MX2013006874 A MX 2013006874A MX 2013006874 A MX2013006874 A MX 2013006874A MX 2013006874 A MX2013006874 A MX 2013006874A
Authority
MX
Mexico
Prior art keywords
arycyclic compound
continuous arycyclic
compound
continuous
obesity
Prior art date
Application number
MX2013006874A
Other languages
English (en)
Other versions
MX347054B (es
Inventor
Norimitsu Hayashi
Osamu Sakurai
Kunio Saruta
Takashi Goi
Kenji Morokuma
Hidekazu Tsujishima
Hiroaki Sawamoto
Hiroaki Shitama
Ritsuo Imashiro
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of MX2013006874A publication Critical patent/MX2013006874A/es
Publication of MX347054B publication Critical patent/MX347054B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente es para proporcionar un compuesto aricíclico continuo que tiene una actividad inhibidora de DGAT1 y útil para la profilaxis y/o el tratamiento de obesidad o hiperlipidemia causada por la obesidad, hipertrigliceridemia, trastorno de metabolismo lipídico, hígado graso, hipertensión, arteriosclerosis, diabetes, etc. así como para proporcionar un inhibidor de DGAT1 que comprende el compuesto aricíclico continuo o una sal farmacéuticamente aceptable del mismo como un ingrediente efectivo; se describe el compuesto aricíclico continuo representado por la fórmula: (Ver Formula) en donde los sustituyentes en la fórmula son los mismos que se definen en la especificación o una sal farmacéuticamente aceptable del mismo.
MX2013006874A 2010-12-17 2011-12-16 Compuestos aricíclico continuo. MX347054B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061424365P 2010-12-17 2010-12-17
PCT/JP2011/079958 WO2012081736A1 (en) 2010-12-17 2011-12-16 Continuous arycyclic compound

Publications (2)

Publication Number Publication Date
MX2013006874A true MX2013006874A (es) 2013-07-05
MX347054B MX347054B (es) 2017-04-07

Family

ID=46244825

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006874A MX347054B (es) 2010-12-17 2011-12-16 Compuestos aricíclico continuo.

Country Status (18)

Country Link
US (2) US9302996B2 (es)
EP (1) EP2651915B1 (es)
JP (1) JP5629380B2 (es)
KR (1) KR101530141B1 (es)
CN (1) CN103261185B (es)
AU (1) AU2011342039B2 (es)
BR (1) BR112013014966B1 (es)
CA (1) CA2821900C (es)
DK (1) DK2651915T3 (es)
ES (1) ES2586385T3 (es)
HK (1) HK1188597A1 (es)
HU (1) HUE029002T2 (es)
MX (1) MX347054B (es)
PL (1) PL2651915T3 (es)
PT (1) PT2651915T (es)
RU (1) RU2538964C1 (es)
TW (1) TWI537257B (es)
WO (1) WO2012081736A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2862856B1 (en) * 2012-06-15 2018-08-01 Mitsubishi Tanabe Pharma Corporation Imidazole and triazole compounds as dgat-1 inhibitors
JP5721032B2 (ja) * 2012-06-15 2015-05-20 田辺三菱製薬株式会社 医薬組成物
DK3013796T3 (da) * 2013-06-27 2020-03-16 Lg Chemical Ltd Biarylderivater som gpr120-agonister
US9988374B2 (en) 2014-08-11 2018-06-05 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
SG11201702115SA (en) * 2014-09-17 2017-04-27 Prevacus Inc Synthesis of ent-progesterone and intermediates thereof
MY189770A (en) * 2014-12-24 2022-03-04 Lg Chemical Ltd Biaryl derivative as gpr120 agonists
JP2018501279A (ja) 2014-12-31 2018-01-18 アンギオン バイオメディカ コーポレイション 疾患を治療するための方法及び薬剤

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE204262T1 (de) 1991-09-18 2001-09-15 Glaxo Group Ltd Benzanilidderivate als 5-ht1d-antagonisten
RU2109736C1 (ru) 1992-12-17 1998-04-27 Санкио Компани Лимитед Производные бифенила и способ их получения
FI935373A0 (fi) 1993-12-01 1993-12-01 Iws International Inc Kopplingsstycke eller koppling foer ledning
WO1999058518A2 (en) 1998-05-12 1999-11-18 American Home Products Corporation Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
AU2935200A (en) 1999-04-30 2000-11-17 Pfizer Products Inc. Compounds for the treatment of obesity
GB2351081A (en) 1999-06-18 2000-12-20 Lilly Forschung Gmbh Pharmaceutically active imidazoline compounds and analogues thereof
US20030114457A1 (en) 2001-07-09 2003-06-19 Axys Pharmaceuticals, Inc. 2- [5- (5-carbamimidoyl-1H-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors
JP3600832B2 (ja) 2002-01-28 2004-12-15 株式会社富士薬品 新規１，２，４−トリアゾール系化合物
GB0209891D0 (en) 2002-04-30 2002-06-05 Glaxo Group Ltd Novel compounds
CA2523714A1 (en) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Substituted carboxylic acids
AR044152A1 (es) * 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
MX2007003325A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa.
CN101583352A (zh) * 2005-07-29 2009-11-18 拜尔健康护理有限责任公司 治疗肥胖症的联苯氨基酸衍生物的制备和用途
NZ597247A (en) 2006-11-29 2013-06-28 Abbott Lab Inhibitors of diacylglycerol O-acylotransferase type 1 enzyme
JP2008255024A (ja) 2007-04-02 2008-10-23 Banyu Pharmaceut Co Ltd ビアリールアミン誘導体
WO2009011285A1 (ja) 2007-07-13 2009-01-22 Taisho Pharmaceutical Co., Ltd. ヘテロアリールベンゼン化合物
WO2009079593A1 (en) 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Piperazinyl derivatives useful as modulators of the neuropeptide y2 receptor
US8394823B2 (en) 2008-04-11 2013-03-12 Bristol-Myers Squibb Company Triazolopyridine compounds useful as DGAT1 inhibitors
CA2755253A1 (en) 2009-03-18 2010-09-23 Schering Corporation Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
WO2011002067A1 (ja) 2009-07-02 2011-01-06 武田薬品工業株式会社 複素環化合物およびその用途
WO2012009217A1 (en) 2010-07-13 2012-01-19 Merck Sharp & Dohme Corp. Spirocyclic compounds
AU2011282989A1 (en) 2010-07-28 2013-01-10 Merck Sharp & Dohme Corp. Imidazole derivatives
WO2012044567A2 (en) 2010-09-30 2012-04-05 Merck Sharp & Dohme Corp. Imidazole derivatives
WO2012047772A2 (en) 2010-10-07 2012-04-12 Schering Corporation Imidazole derivatives

Also Published As

Publication number Publication date
US20130261128A1 (en) 2013-10-03
EP2651915A4 (en) 2014-05-28
BR112013014966B1 (pt) 2020-02-18
RU2538964C1 (ru) 2015-01-10
US9975871B2 (en) 2018-05-22
HK1188597A1 (en) 2014-05-09
CN103261185A (zh) 2013-08-21
ES2586385T3 (es) 2016-10-14
US20160272614A1 (en) 2016-09-22
WO2012081736A1 (en) 2012-06-21
CA2821900C (en) 2015-12-08
HUE029002T2 (en) 2017-01-30
CA2821900A1 (en) 2012-06-21
AU2011342039B2 (en) 2015-06-11
US9302996B2 (en) 2016-04-05
PL2651915T3 (pl) 2016-11-30
TWI537257B (zh) 2016-06-11
BR112013014966A2 (pt) 2016-09-13
KR101530141B1 (ko) 2015-06-18
CN103261185B (zh) 2014-12-10
MX347054B (es) 2017-04-07
JP2013545719A (ja) 2013-12-26
DK2651915T3 (en) 2016-07-18
KR20130106422A (ko) 2013-09-27
EP2651915B1 (en) 2016-05-25
RU2013132961A (ru) 2015-01-27
TW201305126A (zh) 2013-02-01
EP2651915A1 (en) 2013-10-23
JP5629380B2 (ja) 2014-11-19
PT2651915T (pt) 2016-07-14

Similar Documents

Publication Publication Date Title
MX2013006874A (es) Compuestos ariciclico continuo.
TN2011000400A1 (en) Inhibitors of beta-secretase
NZ702749A (en) Neprilysin inhibitors
AU2012313888A8 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
IN2014CN03159A (es)
MY170935A (en) Neprilysin inhibitors
SG191175A1 (en) Neprilysin inhibitors
MY193277A (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
MY165087A (en) Neprilysin inhibitors
AU2012214029A8 (en) Rorgammat inhibitors
MY163394A (en) Substituted aminobutyric derivates as neprilysin inhibitors
TW201000473A (en) Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
WO2012173682A3 (en) Compounds and methods for the treatment of isocitrate dehydrognase related diseases
WO2008109991A8 (en) Inhibitors of carnitine palmitoyltransferase and treating cancer
RS53617B1 (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
MX2010008460A (es) Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular.
MX2021005494A (es) Composicion farmaceutica que comprende un derivado de amida que inhibe el crecimiento de celulas con cancer y lubricante de sal no metalica.
WO2011123536A8 (en) Polycyclic tetracycline compounds
WO2009015485A8 (en) Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer
UA105527C2 (uk) Сполука-інгібітор матриптази для лікування раку
IN2012DN02502A (es)
WO2010129057A3 (en) Tetracycline compounds
WO2010132670A3 (en) Pentacycline compounds
MX343540B (es) Compuesto de tiazol y metodo de preparacion y uso del mismo.
NZ605804A (en) New aminopyrazoloquinazolines

Legal Events

Date Code Title Description
FG Grant or registration